(Reuters) – A third dose of Pfizer Inc and BioNTech’s COVID vaccine produced significant protection against the Omicron variant in healthy children aged between 5 and 11 years in a trial, the companies said on Thursday. Read full story
(Reuters) – A third dose of Pfizer Inc and BioNTech’s COVID vaccine produced significant protection against the Omicron variant in healthy children aged between 5 and 11 years in a trial, the companies said on Thursday. Read full story